Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-02

AUTHORS

Sk. Md. Fazle Akbar, Shinya Furukawa, Seiji Nakanishi, Masanori Abe, Norio Horiike, Morikazu Onji

ABSTRACT

BackgroundThe therapeutic efficacy of bezafibrate, a hypolipidemic drug, has been shown in patients with primary biliary cirrhosis (PBC) in some pilot studies; however, little is known regarding the mechanism of action of bezafibrate in PBC. This study was conducted to evaluate the therapeutic efficacy, as well as to gain insight about the possible mechanism of action, of bezafibrate in PBC.MethodsSixteen patients with PBC were administered with bezafibrate (400 mg/day) either with (n = 10) or without ursodeoxycholic acid (UDCA; n = 6). The peripheral blood of these patients was collected before and at different times after therapy commencement, and antigen-presenting dendritic cells (DCs) were then cultured. The DCs were enriched and cultured with Staphylococcus aureus Cowan strain-1 for 48 h to evaluate their capacity to produce nitrite.ResultsOne month after the start of bezafibrate therapy, the serum levels of alkaline phosphatase (P = 0.0005), γ-glutamyl transpeptidase (P = 0.0006), total cholesterol (P = 0.0072), and immunoglobulin M (P = 0.0281) were decreased significantly compared to those before patients started bezafibrate therapy. The levels of nitrite produced by DCs decreased in all patients with PBC within 1 month of commencement of bezafibrate therapy. Moreover, decreased nitrite production by DCs was also seen when nitrite production was evaluated 1 year after the start of bezafibrate therapy.ConclusionsThis study reconfirms the therapeutic efficacy of bezafibrate in patients with PBC, including those with UDCA-resistant PBC. Downregulation of nitrite production by DCs may have some relationship with the therapeutic efficacy of bezafibrate; however, further study will be needed to clarify whether or not the antiinflammatory activity of bezafibrate is mediated through nitrite production. More... »

PAGES

157-163

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00535-004-1518-3

DOI

http://dx.doi.org/10.1007/s00535-004-1518-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1015071984

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15770399


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bezafibrate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypolipidemic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Cirrhosis, Biliary", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Liver Function Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Nitrites", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan", 
          "id": "http://www.grid.ac/institutes/grid.255464.4", 
          "name": [
            "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fazle Akbar", 
        "givenName": "Sk. Md.", 
        "id": "sg:person.07516441467.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07516441467.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan", 
          "id": "http://www.grid.ac/institutes/grid.255464.4", 
          "name": [
            "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Furukawa", 
        "givenName": "Shinya", 
        "id": "sg:person.0644725370.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644725370.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan", 
          "id": "http://www.grid.ac/institutes/grid.255464.4", 
          "name": [
            "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakanishi", 
        "givenName": "Seiji", 
        "id": "sg:person.01363402632.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363402632.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan", 
          "id": "http://www.grid.ac/institutes/grid.255464.4", 
          "name": [
            "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Abe", 
        "givenName": "Masanori", 
        "id": "sg:person.014763264214.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014763264214.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan", 
          "id": "http://www.grid.ac/institutes/grid.255464.4", 
          "name": [
            "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Horiike", 
        "givenName": "Norio", 
        "id": "sg:person.0732724765.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732724765.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan", 
          "id": "http://www.grid.ac/institutes/grid.255464.4", 
          "name": [
            "Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Onji", 
        "givenName": "Morikazu", 
        "id": "sg:person.0723653552.71", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723653552.71"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2005-02", 
    "datePublishedReg": "2005-02-01", 
    "description": "BackgroundThe therapeutic efficacy of bezafibrate, a hypolipidemic drug, has been shown in patients with primary biliary cirrhosis (PBC) in some pilot studies; however, little is known regarding the mechanism of action of bezafibrate in PBC. This study was conducted to evaluate the therapeutic efficacy, as well as to gain insight about the possible mechanism of action, of bezafibrate in PBC.MethodsSixteen patients with PBC were administered with bezafibrate (400\u2009mg/day) either with (n = 10) or without ursodeoxycholic acid (UDCA; n = 6). The peripheral blood of these patients was collected before and at different times after therapy commencement, and antigen-presenting dendritic cells (DCs) were then cultured. The DCs were enriched and cultured with Staphylococcus aureus Cowan strain-1 for 48\u2009h to evaluate their capacity to produce nitrite.ResultsOne month after the start of bezafibrate therapy, the serum levels of alkaline phosphatase (P = 0.0005), \u03b3-glutamyl transpeptidase (P = 0.0006), total cholesterol (P = 0.0072), and immunoglobulin M (P = 0.0281) were decreased significantly compared to those before patients started bezafibrate therapy. The levels of nitrite produced by DCs decreased in all patients with PBC within 1 month of commencement of bezafibrate therapy. Moreover, decreased nitrite production by DCs was also seen when nitrite production was evaluated 1 year after the start of bezafibrate therapy.ConclusionsThis study reconfirms the therapeutic efficacy of bezafibrate in patients with PBC, including those with UDCA-resistant PBC. Downregulation of nitrite production by DCs may have some relationship with the therapeutic efficacy of bezafibrate; however, further study will be needed to clarify whether or not the antiinflammatory activity of bezafibrate is mediated through nitrite production.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00535-004-1518-3", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1009747", 
        "issn": [
          "0944-1174", 
          "1435-5922"
        ], 
        "name": "Journal of Gastroenterology", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "40"
      }
    ], 
    "keywords": [
      "primary biliary cirrhosis", 
      "dendritic cells", 
      "bezafibrate therapy", 
      "therapeutic efficacy", 
      "nitrite production", 
      "biliary cirrhosis", 
      "antigen-presenting dendritic cells", 
      "months of commencement", 
      "levels of nitrite", 
      "mechanism of action", 
      "therapy commencement", 
      "\u03b3-glutamyl transpeptidase", 
      "MethodsSixteen patients", 
      "serum levels", 
      "total cholesterol", 
      "ResultsOne month", 
      "peripheral blood", 
      "ursodeoxycholic acid", 
      "hypolipidemic drugs", 
      "immunoglobulin M", 
      "patients", 
      "antiinflammatory activity", 
      "therapy", 
      "ConclusionsThis study", 
      "pilot study", 
      "efficacy", 
      "bezafibrate", 
      "cirrhosis", 
      "Further studies", 
      "alkaline phosphatase", 
      "months", 
      "strain 1", 
      "possible mechanism", 
      "commencement", 
      "study", 
      "cholesterol", 
      "blood", 
      "drugs", 
      "transpeptidase", 
      "downregulation", 
      "levels", 
      "start", 
      "action", 
      "cells", 
      "years", 
      "mechanism", 
      "different times", 
      "phosphatase", 
      "nitrite", 
      "production", 
      "activity", 
      "acid", 
      "relationship", 
      "time", 
      "capacity", 
      "insights"
    ], 
    "name": "Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis", 
    "pagination": "157-163", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1015071984"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00535-004-1518-3"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15770399"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00535-004-1518-3", 
      "https://app.dimensions.ai/details/publication/pub.1015071984"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-11-24T20:52", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/article/article_405.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00535-004-1518-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00535-004-1518-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00535-004-1518-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00535-004-1518-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00535-004-1518-3'


 

This table displays all metadata directly associated to this object as RDF triples.

188 TRIPLES      20 PREDICATES      91 URIs      83 LITERALS      16 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00535-004-1518-3 schema:about N16d0370bf10c40d4be87f6b4fe2ce476
2 N2aabcff1e1ab4b80a70b7b10011e062d
3 N40d9e439098d44428ae508d37343bf38
4 N52b91ec8e38d46e0a9f1eb6b4de7aac1
5 N52dcdd8705ef4a2e85e4a4d439d7eba7
6 N64b1fc852b4f40bf938220514a0e25b6
7 Nb0a42cef809748338ca24b176c0c6fb0
8 Nc0521490d51a403389d8dbc62b189514
9 Nf436f7943e2e46ad9ce3b395989ad85f
10 anzsrc-for:11
11 anzsrc-for:1103
12 schema:author N0cde696499064660846000915e8c7ebf
13 schema:datePublished 2005-02
14 schema:datePublishedReg 2005-02-01
15 schema:description BackgroundThe therapeutic efficacy of bezafibrate, a hypolipidemic drug, has been shown in patients with primary biliary cirrhosis (PBC) in some pilot studies; however, little is known regarding the mechanism of action of bezafibrate in PBC. This study was conducted to evaluate the therapeutic efficacy, as well as to gain insight about the possible mechanism of action, of bezafibrate in PBC.MethodsSixteen patients with PBC were administered with bezafibrate (400 mg/day) either with (n = 10) or without ursodeoxycholic acid (UDCA; n = 6). The peripheral blood of these patients was collected before and at different times after therapy commencement, and antigen-presenting dendritic cells (DCs) were then cultured. The DCs were enriched and cultured with Staphylococcus aureus Cowan strain-1 for 48 h to evaluate their capacity to produce nitrite.ResultsOne month after the start of bezafibrate therapy, the serum levels of alkaline phosphatase (P = 0.0005), γ-glutamyl transpeptidase (P = 0.0006), total cholesterol (P = 0.0072), and immunoglobulin M (P = 0.0281) were decreased significantly compared to those before patients started bezafibrate therapy. The levels of nitrite produced by DCs decreased in all patients with PBC within 1 month of commencement of bezafibrate therapy. Moreover, decreased nitrite production by DCs was also seen when nitrite production was evaluated 1 year after the start of bezafibrate therapy.ConclusionsThis study reconfirms the therapeutic efficacy of bezafibrate in patients with PBC, including those with UDCA-resistant PBC. Downregulation of nitrite production by DCs may have some relationship with the therapeutic efficacy of bezafibrate; however, further study will be needed to clarify whether or not the antiinflammatory activity of bezafibrate is mediated through nitrite production.
16 schema:genre article
17 schema:isAccessibleForFree false
18 schema:isPartOf N7a607cf3da00401abef1acb08b7be74e
19 Nc0923ae2ffe546e496111ef09eeb51b5
20 sg:journal.1009747
21 schema:keywords ConclusionsThis study
22 Further studies
23 MethodsSixteen patients
24 ResultsOne month
25 acid
26 action
27 activity
28 alkaline phosphatase
29 antigen-presenting dendritic cells
30 antiinflammatory activity
31 bezafibrate
32 bezafibrate therapy
33 biliary cirrhosis
34 blood
35 capacity
36 cells
37 cholesterol
38 cirrhosis
39 commencement
40 dendritic cells
41 different times
42 downregulation
43 drugs
44 efficacy
45 hypolipidemic drugs
46 immunoglobulin M
47 insights
48 levels
49 levels of nitrite
50 mechanism
51 mechanism of action
52 months
53 months of commencement
54 nitrite
55 nitrite production
56 patients
57 peripheral blood
58 phosphatase
59 pilot study
60 possible mechanism
61 primary biliary cirrhosis
62 production
63 relationship
64 serum levels
65 start
66 strain 1
67 study
68 therapeutic efficacy
69 therapy
70 therapy commencement
71 time
72 total cholesterol
73 transpeptidase
74 ursodeoxycholic acid
75 years
76 γ-glutamyl transpeptidase
77 schema:name Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis
78 schema:pagination 157-163
79 schema:productId N282b4f587d18405ea9ed20e9dfa4a153
80 N3dfe871483344182b9c8bec99a9a76a0
81 Nd90a0f35c9e04e6eaf57388f4145fc2e
82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015071984
83 https://doi.org/10.1007/s00535-004-1518-3
84 schema:sdDatePublished 2022-11-24T20:52
85 schema:sdLicense https://scigraph.springernature.com/explorer/license/
86 schema:sdPublisher N2e22c96062cf426e8ecb44c2da310eb8
87 schema:url https://doi.org/10.1007/s00535-004-1518-3
88 sgo:license sg:explorer/license/
89 sgo:sdDataset articles
90 rdf:type schema:ScholarlyArticle
91 N0cde696499064660846000915e8c7ebf rdf:first sg:person.07516441467.66
92 rdf:rest N7b9ef833799d46ac9202186785b82bb1
93 N16d0370bf10c40d4be87f6b4fe2ce476 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Nitrites
95 rdf:type schema:DefinedTerm
96 N282b4f587d18405ea9ed20e9dfa4a153 schema:name pubmed_id
97 schema:value 15770399
98 rdf:type schema:PropertyValue
99 N2aabcff1e1ab4b80a70b7b10011e062d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
100 schema:name Liver Cirrhosis, Biliary
101 rdf:type schema:DefinedTerm
102 N2e22c96062cf426e8ecb44c2da310eb8 schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 N3dfe871483344182b9c8bec99a9a76a0 schema:name dimensions_id
105 schema:value pub.1015071984
106 rdf:type schema:PropertyValue
107 N40d9e439098d44428ae508d37343bf38 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
108 schema:name Middle Aged
109 rdf:type schema:DefinedTerm
110 N52b91ec8e38d46e0a9f1eb6b4de7aac1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
111 schema:name Hypolipidemic Agents
112 rdf:type schema:DefinedTerm
113 N52dcdd8705ef4a2e85e4a4d439d7eba7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Liver Function Tests
115 rdf:type schema:DefinedTerm
116 N64b1fc852b4f40bf938220514a0e25b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Adult
118 rdf:type schema:DefinedTerm
119 N7a607cf3da00401abef1acb08b7be74e schema:volumeNumber 40
120 rdf:type schema:PublicationVolume
121 N7b9ef833799d46ac9202186785b82bb1 rdf:first sg:person.0644725370.29
122 rdf:rest N8cd92cc425a84afaa66f47ff4fadffaa
123 N8cd92cc425a84afaa66f47ff4fadffaa rdf:first sg:person.01363402632.78
124 rdf:rest N986cd9f851d34b888f2dad781e9c643d
125 N986cd9f851d34b888f2dad781e9c643d rdf:first sg:person.014763264214.31
126 rdf:rest Ne093f745f07c41969097567e594a4c22
127 Naa4a0df6fd11415095edc91eca4bcf34 rdf:first sg:person.0723653552.71
128 rdf:rest rdf:nil
129 Nb0a42cef809748338ca24b176c0c6fb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Bezafibrate
131 rdf:type schema:DefinedTerm
132 Nc0521490d51a403389d8dbc62b189514 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 Nc0923ae2ffe546e496111ef09eeb51b5 schema:issueNumber 2
136 rdf:type schema:PublicationIssue
137 Nd90a0f35c9e04e6eaf57388f4145fc2e schema:name doi
138 schema:value 10.1007/s00535-004-1518-3
139 rdf:type schema:PropertyValue
140 Ne093f745f07c41969097567e594a4c22 rdf:first sg:person.0732724765.18
141 rdf:rest Naa4a0df6fd11415095edc91eca4bcf34
142 Nf436f7943e2e46ad9ce3b395989ad85f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Female
144 rdf:type schema:DefinedTerm
145 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
146 schema:name Medical and Health Sciences
147 rdf:type schema:DefinedTerm
148 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
149 schema:name Clinical Sciences
150 rdf:type schema:DefinedTerm
151 sg:journal.1009747 schema:issn 0944-1174
152 1435-5922
153 schema:name Journal of Gastroenterology
154 schema:publisher Springer Nature
155 rdf:type schema:Periodical
156 sg:person.01363402632.78 schema:affiliation grid-institutes:grid.255464.4
157 schema:familyName Nakanishi
158 schema:givenName Seiji
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01363402632.78
160 rdf:type schema:Person
161 sg:person.014763264214.31 schema:affiliation grid-institutes:grid.255464.4
162 schema:familyName Abe
163 schema:givenName Masanori
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014763264214.31
165 rdf:type schema:Person
166 sg:person.0644725370.29 schema:affiliation grid-institutes:grid.255464.4
167 schema:familyName Furukawa
168 schema:givenName Shinya
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0644725370.29
170 rdf:type schema:Person
171 sg:person.0723653552.71 schema:affiliation grid-institutes:grid.255464.4
172 schema:familyName Onji
173 schema:givenName Morikazu
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0723653552.71
175 rdf:type schema:Person
176 sg:person.0732724765.18 schema:affiliation grid-institutes:grid.255464.4
177 schema:familyName Horiike
178 schema:givenName Norio
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0732724765.18
180 rdf:type schema:Person
181 sg:person.07516441467.66 schema:affiliation grid-institutes:grid.255464.4
182 schema:familyName Fazle Akbar
183 schema:givenName Sk. Md.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07516441467.66
185 rdf:type schema:Person
186 grid-institutes:grid.255464.4 schema:alternateName Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan
187 schema:name Third Department of Intenal Medicine, Ehime University School of Medicine, 791-0295, Ehime, Shigenobu-Cho, Japan
188 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...